AKA Reddit Mentions | ChartExchange

*Obligatory: This is not financial advice. I'm just a smooth-brain ape who eats crayons and somehow learned to type. My wife's boyfriend helped me with the big words. Do your own DD.*
# TL;DR for Apes Who Can't Read Good
Listen up degenerates, I found a stonk trading at **$0.86** with **$2.16 cash per share**. That's right, the hedgies are literally PAYING YOU $1.30/share to own a commercial-stage oncology company. Market cap: $100M. Cash: $250M. Short interest: 28.8%. This thing is more coiled than your wife's boyfriend's bedsprings.
Potential tendies: **400-600% upside** according to the wrinkle-brains at Wall Street. Earnings catalyst July 31st. Position: Long CHRS, short my remaining brain cells.
# The Setup: From Biosimilar Boomer to Oncology Chad
Alright you beautiful autists, gather 'round for a tale of corporate transformation that would make even the most jaded WSB veteran shed a tear. Coherus BioSciences (NASDAQ: CHRS) just pulled off the most galaxy-brain strategic pivot since Netflix ditched DVDs.
**The Master Plan:**
* CEO Dennis "Diamond Hands" Lanfear looked at his biosimilar portfolio and said "fuck it, we're going full oncology mode"
* Sold CIMERLI for $170M (absolute chad move)
* Yeeted YUSIMRY for $40M
* Absolutely DUNKED on the market by selling UDENYCA for $483.4M
Total haul: **$750M+ in cold hard cash**. What did they do with these tendies? Did they YOLO into 0DTE SPY calls like true degenerates? No, these absolute madlads:
* Paid off $230M in debt (responsible AF)
* Cut 30% of workforce to save $25M/year (lean and mean)
* Now sitting on $250M cash with ZERO debt
* Cash runway to 2027 (no dilution for you bag holders)
# The Numbers That Made My Smooth Brain Grow Wrinkles
**Current Situation (Not a Meme):**
* Stock Price: $0.86 (literally can't go tits up... right?)
* Shares Outstanding: 115.9M
* Market Cap: \~$100M (smaller than DFV's gains)
* Cash on Hand: \~$250M (yes, you read that right)
* Enterprise Value: **NEGATIVE $150M**
Let me spell this out for the extra smooth brains: The market is valuing this company at NEGATIVE value. It's like going to GameStop and them paying YOU to take a PS5. Except this isn't a dying brick-and-mortar, it's a company with FDA-approved cancer drugs.
**Valuation Metrics (For the Quants Among Us):**
* P/S Ratio: 0.3x (biotech median is 8x+ you absolute donkeys)
* Cash/Share: $2.16 vs Stock Price: $0.86
* Price/Book: Below book value (bears r fuk)
* EV/Sales: Literally negative (hedgies in shambles)
# Meet the Silverback: CEO Dennis "Big Dick Energy" Lanfear
This absolute unit co-founded Coherus in 2010 and has been diamond-handing his position ever since:
* Former Amgen VP (knows his shit about biologics)
* Raised $1.25 BILLION+ (makes your portfolio look like lunch money)
* Built one of the first U.S. biosimilar companies (OG disruptor)
* Currently owns 1.25M shares (skin in the game)
* 2023 comp: $5.9M (reasonable for turning water into wine)
This isn't some pump-and-dump CEO. This is a proven operator who just executed a $750M strategic transformation without breaking a sweat.
# The Rocket Fuel: Pipeline That Actually Slaps
# LOQTORZI (The Money Printer)
* **ONLY** FDA-approved treatment for nasopharyngeal carcinoma
* NCCN Preferred status (basically the FDA's favorite child)
* Q1 2025 revenue: $7.3M growing 15%+ quarter-over-quarter
* Peak sales potential: $150-200M within 3 years
* Currently printing money, just needs volume
# Casdozokitug (The Dark Horse)
* First-in-class IL-27 antagonist (fancy science shit)
* Phase 2 data: **38% response rate, 17% complete responses**
* FDA Fast Track designation (regulatory tendies incoming)
* Data readout 1H 2026 (mark your calendars)
# CHS-114 (The Sleeper Hit)
* Targets CCR8 on regulatory T cells (kills the bad guys, spares the good guys)
* Showed responses in heavily pretreated patients (these people had no options left)
* Multiple Phase 1b studies ongoing
* Designed to combo with LOQTORZI (1+1=3 math)
# The Bear Thesis (AKA FUD Distribution Center)
Look, I'm not gonna blow smoke up your ass. This isn't risk-free tendies:
**Why This Could Go Tits Up:**
* Revenue dropped 79% after selling biosimilars (temporary pain for permanent gains)
* Currently burning cash (but have 2+ years worth)
* Stock under $1 (Nasdaq compliance issues, potential reverse split)
* Competing against Big Pharma chads with infinite money glitches
* Pipeline could fail (but that's why we have multiple shots)
**The Smooth Brain Take:** Yeah there's risk, but at negative EV you're basically getting paid to take it.
# The Analyst Circle Jerk
Wall Street can't decide if this is going to zero or the moon:
* Consensus: **$4-6.50 price target** (400-600% upside)
* Range: $1.05 (UBS being gay bears) to $7+ (HC Wainwright with the hopium)
* 4 Buys, 3 Holds, 0 Sells (nobody has the balls to go full bear)
Recent moves:
* HC Wainwright: "Buy at $7" (March 2025, absolute chads)
* Baird: Raised to $6 from $4 (December 2024, starting to believe)
* UBS: "$1.05 Neutral" (August 2024, probably short)
# The Squeeze Setup That Has Me Fully Torqued
**Short Interest Data (Oh Boy Oh Boy):**
* Shares Short: 31.94M (28.8% of float)
* Days to Cover: **24.2 DAYS** (that's not a typo)
* Borrow Rate: Moon level
* Setup: Convertible hedgers about to get absolutely rekt
For you smooth brains: When 28.8% of the float is short and it takes 24 days to cover at average volume, any positive catalyst turns this into a rocket ship. Remember GME? This has similar mechanics but with actual fundamentals.
**Gamma Ramp Potential:** Sub-$1 stocks = cheap options = degenerate call buying = market maker hedging = stonk go up = more hedging = infinite money glitch activated
# Upcoming Catalysts (Tendies on the Horizon)
**July 31, 2025: Q2 Earnings**
* First clean quarter showing that $250M cash position
* LOQTORZI growth update (15%+ sequential growth continuing?)
* Potential partnership announcements
* Short squeeze ignition potential
**H2 2025 - H1 2026:**
* CHS-114 Phase 1b data drops
* Casdozokitug Phase 2 results
* FDA filing for LOQTORZI in liver cancer
* Any M&A rumors (this company is acquisition bait)
# Position Sizing for Different Risk Tolerances
**For Paper Hands:** Base case $3-4 (modest 300-400% gains, LOQTORZI grows steadily, one pipeline hit)
**For Diamond Hands:** Bull case $6-7 (600%+ gains, multiple approvals, shorts capitulate)
**For True Degenerates:** Moon case $10+ (buyout at 3x cash, pipeline hits on all cylinders, meme stock status achieved)
**For** 🌈🐻: Bear case $1-1.50 (still 20-75% upside from here lmao, bears truly r fuk)
# The Final Word: Why This is THE Play
Listen up you magnificent bastards. In a market where trash companies with no revenue trade at billions in market cap, here's a company with:
* $250M cash
* Zero debt
* FDA-approved drug generating revenue
* Multiple Phase 2 assets
* Proven management
* Trading at HALF its cash value
The hedgies have shorted this into oblivion thinking it's going to zero. They're about to learn what happens when you short a company below its cash value with multiple catalysts incoming.
This is either the easiest 5x of your life or I'll see you behind the Wendy's dumpster. But with $2.16/share in cash backing and trading at $0.86, even if everything goes wrong, you're probably fine.
**Positions:** Long CHRS, Short the entire biosimilar industry, Extra long on hopium
*This is not financial advice. I am literally too stupid to give financial advice. I once tried to buy calls on $ROPE. My investment strategy is based entirely on rocket emojis and whether the ticker makes me giggle. If you lose money following this DD, that's on you for taking advice from someone who thinks "P/E ratio" stands for "Probably Eating crayons." May the tendies be with you, and remember - it literally can't go tits up.*
🚀🚀🚀 CHRS TO VALHALLA 🚀🚀🚀

.dark-mode .N7bkKr{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .N7bkKr{ color: #333333; background-color: white; border: 2px solid #333333; }AKAa.k.a. Brands Holding Corp.stock NYSE

AKA
a.k.a. Brands Holding Corp.
stock NYSE